Q3 EPS Estimates for Relay Therapeutics Cut by HC Wainwright

Relay Therapeutics, Inc. (NASDAQ:RLAY) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Relay Therapeutics in a research report issued on Thursday, August 20th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.37) per share for the quarter, down from their prior forecast of ($0.36). HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Relay Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Relay Therapeutics’ Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.57) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.40) EPS and Q4 2027 earnings at ($0.41) EPS.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The business had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.96 million.

Other research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Monday, July 6th. Guggenheim reaffirmed a “buy” rating on shares of Relay Therapeutics in a research note on Friday, August 7th. Barclays raised their price objective on shares of Relay Therapeutics from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. UBS Group set a $26.00 target price on shares of Relay Therapeutics in a research note on Tuesday, May 19th. Finally, The Goldman Sachs Group boosted their target price on shares of Relay Therapeutics from $22.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.92.

Relay Therapeutics Stock Up 1.6%

Shares of RLAY opened at $19.76 on Monday. The company has a market capitalization of $4.33 billion, a price-to-earnings ratio of -12.59 and a beta of 1.69. Relay Therapeutics has a 52 week low of $3.44 and a 52 week high of $21.27. The stock’s 50-day moving average price is $18.95 and its 200-day moving average price is $14.48.

Insiders Place Their Bets

In other news, insider Peter Rahmer sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the completion of the sale, the insider directly owned 225,857 shares in the company, valued at $4,311,610.13. The trade was a 18.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Sanjiv Patel sold 48,199 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total value of $943,736.42. Following the transaction, the chief executive officer directly owned 615,898 shares of the company’s stock, valued at approximately $12,059,282.84. The trade was a 7.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 409,639 shares of company stock worth $7,233,399. Company insiders own 5.04% of the company’s stock.

Institutional Investors Weigh In On Relay Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its holdings in Relay Therapeutics by 1,726.3% during the second quarter. California State Teachers Retirement System now owns 3,179,652 shares of the company’s stock valued at $59,491,000 after purchasing an additional 3,005,553 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Relay Therapeutics during the second quarter worth about $19,004,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth about $366,000. Moore Capital Management LP acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth about $7,746,000. Finally, Two Sigma Securities LLC purchased a new position in Relay Therapeutics in the 2nd quarter valued at about $214,000. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.